Over the last 20 years, Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Health’s Perlmutter Cancer Center, has used immunotherapies called checkpoint inhibitors to successfully treat people with melanoma. As part of the Cancer Research Institute’s 2022 Virtual Immunotherapy Patient Summit, he discusses different stages of melanoma, how immunotherapy has advanced the treatment of melanoma, and why some people do not respond to immunotherapy.

“I think it’s a very important thing that we now have truly effective drugs for melanoma, and checkpoint inhibitors really have changed the face of cancer therapy in general, not just in melanoma,” says Dr. Weber, who is also the Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine.

Watch more from the Cancer Research Institute.